Geo News
Community curated by people like you
LatestAICryptoHealthWorld AffairsUS Politics

Parkinson's disease stories

Nov 15, 2026

Oyster Therapeutics raises $60M for brain-penetrating small molecule degraders

Brain-focused startup Oyster Therapeutics secured $60 million to advance its lead program targeting pathological tau in Alzheimer's disease, with Eli Lilly participating in the round.

Nov 15, 2026·3 sources
00
Apr 20, 2026

Gut Microbiome Analysis Can Predict Parkinson's Disease Risk Before Symptoms Appear

New research led by University College London shows that analysis of gut microbes can reveal elevated Parkinson's disease risk before any symptoms develop, offering potential for early intervention.

Apr 20, 2026·1 source
00
Apr 11, 2026

Experimental Parkinson's Drug Reduces Disease-Linked Protein by Up to 60% in First Human Trial

An experimental drug designed to silence a gene strongly linked to Parkinson's disease showed encouraging effects in reducing the target protein by up to 60% in a first-in-human clinical trial published in Nature Medicine.

Apr 11, 2026·1 source
00

Top claims

  • ▪London-based Oyster Therapeutics raised $60 million in Series A-2 funding to advance its preclinical brain-penetrating small molecule degrader research in Alzheimer's disease
  • ▪Biogen reported preliminary Phase 2 data in May 2026 showing tau reduction and cognitive benefit for its antisense oligonucleotide diranersen, though the trial missed its main dose-response goal at week 76
  • ▪Oyster Therapeutics' $60 million Series A-2 round was led by 4BIO Capital, with participation from new investors Eli Lilly, Actium Group, CE Ventures, and TOHO Ventures

Topics

Neurodegenerative diseaseAlzheimer’s & dementiaAlzheimer's diseaseBiotech innovationVenture capital fundingDrug developmentDrug discoveryBiotech startupEli LillyLongevity & biohackingLifestyle, Wellness and NutritionDiet & nutritionClinical Trial Design & EvaluationDrug Approval and Clinical TrialsClinical evaluationAge related cognitive declineDrug Policy, Pricing & ApprovalLongevity & aging

Related entities

LondonPreventive medicine